Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01365000 · ClinicalTrials.gov registry record · Phase 1

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target

NCT01365000: Completed Phase 1 study, sponsored by AstraZeneca.

NCT01365000 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01365000, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target

Study Summary

The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.

Interventions

  • DRUG NKTR118 Formulation 1
  • DRUG NKTR118 Formulation 2
  • DRUG NKTR118 Formulation 3
  • DRUG NKTR118 Formulation 1a
  • DRUG NKTR118 Formulation 3a

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2011-06
Est. Completion 2011-08
Phase Phase 1
AstraZeneca

1,285 total trials

What the finished NCT01365000 record still lists

NCT01365000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).

The record links to 0 conditions, and to 5 interventions - of which NKTR118 Formulation 1 is the first listed.

NCT01365000 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01365000 about?

NCT01365000 is a clinical study titled "Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects". The is an assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects.

What is the current status of trial NCT01365000?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-06. Estimated completion is 2011-08.

What interventions are being tested in trial NCT01365000?

The interventions under investigation include: NKTR118 Formulation 1 (DRUG), NKTR118 Formulation 2 (DRUG), NKTR118 Formulation 3 (DRUG), NKTR118 Formulation 1a (DRUG), NKTR118 Formulation 3a (DRUG).

Who is sponsoring clinical trial NCT01365000?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01365000's enrollment target sits among peer trials

21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01365000, the US trial registry maintained by the National Library of Medicine. NCT01365000 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.